The goal of drug repositioning is to expedite the drug development process by finding novel therapeutic applications for approved drugs. Using multifeature learning, different computational drug repositioning techniques have recently been introduced to predict possible drug-disease relationships. Nevertheless, current graph-based methods tend to model drug-disease interaction relationships without considering the semantic influence of node-specific side information on graphs. These approaches also suffer from the noise and sparsity inherent in the data. To address these limitations, we propose MDGCN, a novel drug repositioning method that incorporates multidependency graph convolutional networks and contrastive learning. Based on drug and disease similarity matrices and the drug-disease relationships matrix, this approach constructs multidependency graphs. It subsequently employs graph convolutional networks to spread side information between various graphs in each layer. Meanwhile, the weak supervision of drug-disease connections is effectively addressed by introducing cross-view and cross-layer contrastive learning to align node embedding across various views. Extensive experiments show that MDGCN performs better in drug-disease association prediction than seven advanced methods, offering strong support for investigating novel therapeutic indications for medications of interest.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acs.jcim.4c02424 | DOI Listing |
Sci Adv
March 2025
College of Computer Science and Technology, Zhejiang University, Hangzhou, China.
Brain age gap (BAG), the deviation between estimated brain age and chronological age, is a promising marker of brain health. However, the genetic architecture and reliable targets for brain aging remains poorly understood. In this study, we estimate magnetic resonance imaging (MRI)-based brain age using deep learning models trained on the UK Biobank and validated with three external datasets.
View Article and Find Full Text PDFJ Biomol Struct Dyn
March 2025
School of Mechatronic Engineering and automation, Shanghai University, Shanghai, China.
Prediction of protein-ligand interactions is critical for drug discovery and repositioning. Traditional prediction methods are computationally intensive and limited in modeling structural changes. In contrast, data-driven deep learning methods significantly reduce computational costs and offer a more efficient approach for drug discovery.
View Article and Find Full Text PDFJ Chem Inf Model
March 2025
School of Computer Engineering and Science, Shanghai University, Shanghai 200444, China.
The goal of drug repositioning is to expedite the drug development process by finding novel therapeutic applications for approved drugs. Using multifeature learning, different computational drug repositioning techniques have recently been introduced to predict possible drug-disease relationships. Nevertheless, current graph-based methods tend to model drug-disease interaction relationships without considering the semantic influence of node-specific side information on graphs.
View Article and Find Full Text PDFChem Biol Drug Des
March 2025
Centre in Artificial Intelligence Driven Drug Discovery, Applied Sciences, Macao Polytechnic University, Macao, China.
Methicillin-resistant Staphylococcus aureus (MRSA) achieves high-level resistance against β-lactam antibiotics through the expression of penicillin-binding protein 2a (PBP2a), which features a closed active site that impedes antibiotic binding. Herein, we implemented a strategy that combines drug repurposing with synergistic therapy to identify potential inhibitors targeting PBP2a's allosteric site from an FDA-approved drug database. Initially, retrospective verifications were conducted, employing different Glide docking methods (HTVS, SP, and XP) and two representative PBP2a structures.
View Article and Find Full Text PDFJ Biochem Mol Toxicol
March 2025
Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
Sunitinib (SUN) is a chemotherapeutic agent showing renal toxicity that limits its clinical applications. The present research aimed to clarify the potential ameliorative effects of secukinumab (SEC) and dapagliflozin (DAPA) against SUN-induced renal toxicity and the underpinning molecular mechanisms. For this purpose, adult Wistar albino rats were received SUN (25 mg/kg 3 times/week, po) and co-treated with SEC (3 mg/kg/every 2 weeks, subcutaneously) or DAPA (10 mg/kg/day, po) for 4 weeks and compared with age-matched control group (CON).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!